Merotocin

Drug Profile

Merotocin

Alternative Names: FE-202767

Latest Information Update: 11 Sep 2015

Price : $50

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Hormones; Oxytocics
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lactation failure

Most Recent Events

  • 26 Aug 2015 Ferring Pharmaceuticals plans a phase II trial for Lactation failure in USA (NCT02545127)
  • 12 Mar 2015 Ferring Pharmaceuticals has patent pending for Merotocin
  • 04 Jul 2012 Phase-II clinical trials in Lactation failure (In volunteers) in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top